U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H22I3N3O8
Molecular Weight 789.096
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METRIZAMIDE

SMILES

CN(C(C)=O)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)=C1I

InChI

InChIKey=DTZMSDADRKLCQE-RFMXWLSYSA-N
InChI=1S/C18H22I3N3O8/c1-6(27)22-14-11(19)10(12(20)15(13(14)21)24(3)7(2)28)18(32)23-8(4-25)16(30)17(31)9(29)5-26/h4,8-9,16-17,26,29-31H,5H2,1-3H3,(H,22,27)(H,23,32)/t8-,9+,16+,17+/m0/s1

HIDE SMILES / InChI

Description

Metrizamide is a glucosamine derivative of metrazoic acid, used as a contrast medium for myelography. Metrizamide is no longer marketed in the US.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: The blood-brain barrier of rats is impermeable to metrizamide.

Originator

Almen, T.|Nyegaard
1
Curator's Comment: In 1968, Torsten Almen, working in conjunction with Nyegaard, produced the first clinically acceptable non ionic contrast medium, Amipaque (metrizamide, Winthrop).

Approval Year

1978
87
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8429
AMIPAQUE

Approved Use

Unknown

Launch Date

2.72678404E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.6 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1151624/
1700 mg single, intrathecal
dose: 1700 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
METRIZAMIDE serum
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
208 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1151624/
1700 mg single, intrathecal
dose: 1700 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
METRIZAMIDE serum
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.75 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1151624/
1700 mg single, intrathecal
dose: 1700 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
METRIZAMIDE serum
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.0351966873706 g/kg single, intravenous
Highest studied dose
Dose: 1.0351966873706 g/kg
Route: intravenous
Route: single
Dose: 1.0351966873706 g/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/433646
unhealthy, 32 - 71 years
n = 11
Health Status: unhealthy
Age Group: 32 - 71 years
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/433646
Sources:
https://pubmed.ncbi.nlm.nih.gov/433646
Sourcing

Sourcing

Vendor/AggregatorIDURL
MolPort
MolPort-046-857-011
TimTec
ST51006711
ZINC
ZINC000150485244
http://zinc15.docking.org/substances/ZINC000150485244
PubMed

PubMed

TitleDatePubMed
Metrizamide-phenothiazine interaction. Report of a case with seizures following myelography.
1975 Mar
ECG changes and arrhythmias induced by ionic and non-ionic contrast media during coronary arteriography in dogs.
1978 May-Jun
Metrizamide--a potential in vivo inhibitor of glucose metabolism.
1983 Apr
Absence status epilepticus resulting from metrizamide and omnipaque myelography.
1988 Jan
Risk of seizures after myelography: comparison of iohexol and metrizamide.
1988 Sep
A possible mechanism for the neural adverse reactions caused by metrizamide.
1989
Malignant hyperthermia-like syndrome associated with metrizamide myelography.
1989 Jun
Patents

Patents

JP2002539853A
1
JP2002543940A
2
JP2011511651A
2

Sample Use Guides

In Vivo Use Guide
300 mgI/ml as one injection
Route of Administration: Intra-arterial
In Vitro Use Guide
Cultured endothelial cells derived from human umbilical cord veins were labeled with Na2 (51Cr)O4 and exposed to pure isoiodinated contrast media or control solutions for 10 minutes to simulate the effects of intravenous injections of contrast media on the human endothelium. Metrizamide was used at 300 mgI/ml.
Name Type Language
METRIZAMIDE
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
WIN 39103
Code English
D-GLUCOSE, 2-((3-(ACETYLAMINO)-5-(ACETYLMETHYLAMINO)-2,4,6-TRIIODOBENZOYL)AMINO)-2-DEOXY-
Systematic Name English
WIN-39103
Code English
3-ACETAMIDO-2,4,6-TRIIODO-5-(N-METHYLACETAMIDO)-N-((2R,3R,4S,5R)-3,4,5,6-TETRAHYDROXY-1-OXOHEXAN-2-YL)BENZAMIDE
Systematic Name English
2-(3-ACETAMIDO-2,4,6-TRIIODO-5-(N-METHYLACETAMIDO)BENZAMIDO)-2-DEOXY-D-GLUCOPYRANOSE
Systematic Name English
3-ACETAMIDO-2,4,6-TRIIODO-5-(N-METHYLACETAMIDO)-N-((3R,4R,5S,6R)-2,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3-YL)BENZAMIDE
Systematic Name English
AMIPAQUE
Brand Name English
METRIZAMIDE [MART.]
Common Name English
METRIZAMIDE [VANDF]
Common Name English
TELEBRIX 300
Brand Name English
metrizamide [INN]
Common Name English
METRIZAMIDE [ORANGE BOOK]
Common Name English
2-(3-ACETAMIDO-2,4,6-TRIIODO-5-(N-METHYLACETAMIDO)BENZAMIDO)-2-DEOXY-D-GLUCOSE
Systematic Name English
METRIZAMIDE [MI]
Common Name English
METRIZAMIDE [JAN]
Common Name English
Metrizamide [WHO-DD]
Common Name English
METRIZAMIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C390
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
WHO-VATC QV08AB01
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
WHO-ATC V08AB01
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
Code System Code Type Description
INN
3116
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
MERCK INDEX
m7504
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY Merck Index
CAS
55134-11-7
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
ALTERNATIVE
ChEMBL
CHEMBL1200889
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID1023310
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
FDA UNII
RHH3W8F1CO
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
DRUG CENTRAL
1788
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
DRUG BANK
DB01578
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
MESH
D008793
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
EVMPD
SUB08921MIG
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
NCI_THESAURUS
C66139
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
SMS_ID
100000080928
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
PUBCHEM
20056604
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
RXCUI
6920
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY RxNorm
CAS
31112-62-6
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
WIKIPEDIA
METRIZAMIDE
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
ECHA (EC/EINECS)
250-475-5
Created by admin on Fri Dec 15 16:16:55 UTC 2023 , Edited by admin on Fri Dec 15 16:16:55 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of METRIZAMIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966